Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Shares Shorted: Short Interest Down 38.8% in October

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a significant drop in short interest in October. As of October 15th, there was short interest totaling 15,751 shares, a drop of 38.8% from the September 30th total of 25,736 shares. Currently, 0.9% of the shares of the stock are short sold. Based on an average trading volume of 26,150 shares, the short-interest ratio is currently 0.6 days.

Insider Buying and Selling

In related news, CEO William Quinn sold 9,132 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $3.24, for a total value of $29,587.68. Following the sale, the chief executive officer directly owned 25,384 shares in the company, valued at approximately $82,244.16. The trade was a 26.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 38,584 shares of company stock valued at $128,361. 9.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bolt Biotherapeutics stock. Nan Fung Group Holdings Ltd bought a new position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,000 shares of the company’s stock, valued at approximately $19,250. Bolt Biotherapeutics comprises 0.0% of Nan Fung Group Holdings Ltd’s portfolio, making the stock its 25th biggest holding. Nan Fung Group Holdings Ltd owned approximately 0.26% of Bolt Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 86.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $14.50.

Bolt Biotherapeutics Price Performance

Shares of BOLT opened at $6.59 on Friday. The firm has a 50-day simple moving average of $4.14 and a two-hundred day simple moving average of $4.52. The stock has a market cap of $12.72 million, a PE ratio of -0.40 and a beta of 1.00. Bolt Biotherapeutics has a 1-year low of $3.10 and a 1-year high of $7.78. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.61 and a quick ratio of 2.61.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($4.57) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.18). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%. As a group, analysts forecast that Bolt Biotherapeutics will post -11.10 EPS for the current year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment.

Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.